Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel
| Autor: | Michal Solomon, Felix Pavlotzky, Aviv Barzilai, Eli Schwartz, Charles L. Jaffe, Abedelmajeed Nasereddin, Nadav Sahar |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Leishmaniasis
Mucocutaneous Male Epidemiology lcsh:Medicine Gastroenterology Leishmania viannia braziliensis 0302 clinical medicine Communicable Diseases Imported Risk Factors Mucosal leishmaniasis 030212 general & internal medicine Israel Pathology Molecular Leishmania braziliensis complex biology mucosal leishmaniasis Infectious Diseases travelers Synopsis CL Female Travel-Related Illness Adult Microbiology (medical) Bolivia medicine.medical_specialty 030231 tropical medicine parasites Leishmania braziliensis lcsh:Infectious and parasitic diseases Diagnosis Differential 03 medical and health sciences cutaneous leishmaniasis Cutaneous leishmaniasis Internal medicine medicine Humans lcsh:RC109-216 Skin Diseases Parasitic leishmaniasis Retrospective Studies Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel business.industry lcsh:R Leishmaniasis Retrospective cohort study medicine.disease biology.organism_classification Leishmania ML Complication business |
| Zdroj: | Emerging Infectious Diseases, Vol 25, Iss 4, Pp 642-648 (2019) Emerging Infectious Diseases |
| ISSN: | 1080-6059 1080-6040 |
| Popis: | Mucosal leishmaniasis (ML) is a complication of New World cutaneous leishmaniasis (CL) caused mainly by Leishmania (Viannia) braziliensis. This retrospective study investigated all cases of ML caused by L. (V.) braziliensis in a tertiary medical center in Israel, evaluating the risk factors, clinical presentations, diagnosis, treatment, and outcome of mucosal involvement in ML caused by L. (V.) braziliensis in travelers returning to Israel. During 1993-2015, a total of 145 New World CL cases were seen in travelers returning from Bolivia; among them, 17 (11.7%) developed ML. Nasopharyngeal symptoms developed 0-3 years (median 8 months) after exposure. The only significant risk factor for developing ML was the absence of previous systemic treatment. Among untreated patients, 41% developed ML, compared with only 3% of treated patients (p = 0.005). Systemic treatment for CL seems to be a protective factor against developing ML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|